Omeros (OMER) Competitors $9.18 -0.43 (-4.47%) Closing price 04:00 PM EasternExtended Trading$9.46 +0.29 (+3.10%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends OMER vs. PCRX, NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, and BMYShould you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), and Bristol-Myers Squibb (BMY). These companies are all part of the "pharmaceuticals" industry. Omeros vs. Pacira BioSciences Nektar Therapeutics Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Pfizer Bristol-Myers Squibb Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk. Do institutionals and insiders hold more shares of OMER or PCRX? 48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 12.3% of Omeros shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, OMER or PCRX? Omeros has a beta of 1.98, suggesting that its share price is 98% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Does the MarketBeat Community prefer OMER or PCRX? Pacira BioSciences received 79 more outperform votes than Omeros when rated by MarketBeat users. Likewise, 71.43% of users gave Pacira BioSciences an outperform vote while only 71.05% of users gave Omeros an outperform vote. CompanyUnderperformOutperformOmerosOutperform Votes74671.05% Underperform Votes30428.95% Pacira BioSciencesOutperform Votes82571.43% Underperform Votes33028.57% Does the media prefer OMER or PCRX? In the previous week, Pacira BioSciences had 18 more articles in the media than Omeros. MarketBeat recorded 24 mentions for Pacira BioSciences and 6 mentions for Omeros. Omeros' average media sentiment score of 0.29 beat Pacira BioSciences' score of 0.05 indicating that Omeros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 0 Very Positive mention(s) 2 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is OMER or PCRX more profitable? Omeros has a net margin of 0.00% compared to Pacira BioSciences' net margin of -13.07%. Pacira BioSciences' return on equity of 13.42% beat Omeros' return on equity.Company Net Margins Return on Equity Return on Assets OmerosN/A N/A -49.92% Pacira BioSciences -13.07%13.42%7.19% Do analysts prefer OMER or PCRX? Omeros presently has a consensus target price of $22.50, indicating a potential upside of 145.10%. Pacira BioSciences has a consensus target price of $22.78, indicating a potential downside of 9.47%. Given Omeros' stronger consensus rating and higher possible upside, equities analysts plainly believe Omeros is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Omeros 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80Pacira BioSciences 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 Which has higher earnings and valuation, OMER or PCRX? Pacira BioSciences has higher revenue and earnings than Omeros. Pacira BioSciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOmerosN/AN/A-$117.81M-$2.31-3.97Pacira BioSciences$674.98M1.72$41.96M-$2.03-12.39 SummaryPacira BioSciences beats Omeros on 10 of the 18 factors compared between the two stocks. Get Omeros News Delivered to You Automatically Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OMER vs. The Competition Export to ExcelMetricOmerosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$531.98M$7.04B$5.78B$8.98BDividend YieldN/A2.87%4.78%3.85%P/E Ratio-3.976.1326.4618.82Price / SalesN/A313.78457.6880.73Price / CashN/A67.8344.0437.47Price / Book-22.956.747.634.64Net Income-$117.81M$138.11M$3.18B$245.69M7 Day PerformanceN/A-2.02%-1.82%-2.63%1 Month Performance0.33%-1.54%0.22%-2.37%1 Year Performance116.51%-3.14%17.49%13.65% Omeros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OMEROmeros3.7814 of 5 stars$9.18-4.5%$22.50+145.1%+106.2%$531.98MN/A-3.97210Analyst ForecastNews CoveragePCRXPacira BioSciences3.297 of 5 stars$25.44-4.1%$22.78-10.5%-13.8%$1.17B$674.98M-12.53720NKTRNektar Therapeutics4.1402 of 5 stars$0.98+10.2%$4.08+315.6%+44.2%$181.25M$93.14M-1.17220News CoverageGap UpHigh Trading VolumeASMBAssembly Biosciences4.0854 of 5 stars$13.02+6.6%$35.00+168.8%+14.8%$82.81M$7.16M0.00100News CoverageHigh Trading VolumeCPIXCumberland Pharmaceuticals1.1531 of 5 stars$5.15+11.0%N/A+183.3%$72.31M$39.55M-6.6980Gap DownLLYEli Lilly and Company4.8418 of 5 stars$844.82-3.1%$997.50+18.1%+15.6%$802.01B$45.04B72.1543,000Positive NewsJNJJohnson & Johnson4.5406 of 5 stars$156.20-0.7%$170.67+9.3%+1.1%$376.08B$88.82B23.49131,900Ex-DividendAnalyst ForecastOptions VolumePositive NewsABBVAbbVie4.6487 of 5 stars$193.00-0.2%$208.35+8.0%+14.4%$341.05B$56.33B80.4250,000Dividend AnnouncementAnalyst RevisionPositive NewsMRKMerck & Co., Inc.5 of 5 stars$83.01-1.7%$117.06+41.0%-31.2%$209.99B$64.17B12.3372,000Analyst DowngradeOptions VolumePFEPfizer4.9993 of 5 stars$25.50-0.6%$31.92+25.2%-6.3%$144.48B$63.63B18.0888,000Options VolumePositive NewsBMYBristol-Myers Squibb4.5979 of 5 stars$53.85-3.8%$57.86+7.4%+11.9%$109.22B$48.30B-12.1834,100Analyst RevisionPositive News Related Companies and Tools Related Companies PCRX Alternatives NKTR Alternatives ASMB Alternatives CPIX Alternatives LLY Alternatives JNJ Alternatives ABBV Alternatives MRK Alternatives PFE Alternatives BMY Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:OMER) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Omeros Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Omeros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
